Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LPAA
stocks logo

LPAA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Launch One Acquisition Corp (LPAA.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Launch One Acquisition Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LPAA News & Events

Events Timeline

(ET)
2025-10-15
07:33:36
Minovia Granted Orphan Drug Designation for MNV-201 in Myelodysplastic Syndromes (MDS)
select
2025-09-18 (ET)
2025-09-18
07:32:34
Minovia Granted Fast Track Designation for MNV-201 in MDS
select
2025-08-27 (ET)
2025-08-27
07:19:45
Minovia Receives $350,000 Grant from Countdown for a Cure Foundation
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-20Globenewswire
Minovia תציג את טכנולוגיית הגדלת מיטוכונדריה הטיפולית במצגת ובסדנה בכנס ובתערוכה השנתיים ה-67 של ASH

  • Minovia Therapeutics Presentation: Minovia Therapeutics will present data on its mitochondrial enhancement technology for myelodysplastic syndrome (MDS) at the American Society of Hematology (ASH) annual meeting in December 2025, highlighting the safety and efficacy of its lead product, MNV-201.

  • Clinical Trial Results: MNV-201 has shown a high safety profile in a Phase 1 clinical trial with low-risk MDS patients, with one patient experiencing sustained improvements in hemoglobin levels and mitochondrial function.

  • Business Merger Announcement: Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., aiming to merge and operate under the Minovia Therapeutics name on NASDAQ, with the merger expected to close in early 2026.

  • MDS Overview: MDS is characterized by ineffective hematopoiesis leading to blood cytopenia and an increased risk of acute myeloid leukemia (AML), with treatment goals focused on improving symptoms and quality of life for patients, particularly those diagnosed at an average age of 70.

[object Object]
Preview
9.0
11-20Globenewswire
Minovia Therapeutics' Mitochondrial Augmentation Technology to be Highlighted in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition

  • Mitochondrial Augmentation Technology Presentation: Minovia Therapeutics will present data on its mitochondrial augmentation technology for treating myelodysplastic syndrome (MDS) at the 67th ASH Annual Meeting, highlighting pre-clinical and clinical trial results for its lead product, MNV-201.

  • Positive Clinical Outcomes: MNV-201 has shown a high safety profile in early trials, with one patient achieving transfusion independence and sustained improvements in hemoglobin levels and mitochondrial function biomarkers.

  • Business Combination Agreement: Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., aiming to go public in early 2026 under a new Nasdaq ticker symbol.

  • Focus on Mitochondrial Diseases: Minovia is dedicated to developing therapies for mitochondrial diseases and age-related decline, with ongoing studies for MNV-201 in both MDS and Pearson Syndrome, emphasizing its potential to improve patient outcomes.

[object Object]
Preview
9.0
09-18Globenewswire
Minovia Therapeutics Obtains FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome

  • FDA Fast Track Designation: Minovia Therapeutics has received FDA Fast Track Designation for its leading experimental compound MNV-201, aimed at treating Myelodysplastic Syndrome (MDS), a severe age-related hematologic disease, in addition to existing designations for rare pediatric mitochondrial disorders.

  • Business Combination Agreement: The company has entered into a definitive business combination agreement with Launch One Acquisition Corp, with plans to operate under the name Minovia Therapeutics and trade on NASDAQ under a new symbol following the expected completion of the merger by the end of 2025.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Launch One Acquisition Corp (LPAA) stock price today?

The current price of LPAA is 10.54 USD — it has increased 0.05 % in the last trading day.

arrow icon

What is Launch One Acquisition Corp (LPAA)'s business?

Launch One Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It has not selected any business combination target and the Company has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target. It has no operations nor generated any revenues.

arrow icon

What is the price predicton of LPAA Stock?

Wall Street analysts forecast LPAA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPAA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Launch One Acquisition Corp (LPAA)'s revenue for the last quarter?

Launch One Acquisition Corp revenue for the last quarter amounts to -517.26K USD, increased 172.34 % YoY.

arrow icon

What is Launch One Acquisition Corp (LPAA)'s earnings per share (EPS) for the last quarter?

Launch One Acquisition Corp. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Launch One Acquisition Corp (LPAA)'s fundamentals?

The market is revising No Change the revenue expectations for LPAA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 0.67%.
arrow icon

How many employees does Launch One Acquisition Corp (LPAA). have?

Launch One Acquisition Corp (LPAA) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Launch One Acquisition Corp (LPAA) market cap?

Today LPAA has the market capitalization of 303.03M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free